David Parsons

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Pseudomonas Aeruginosa

Genome Wide Identification

Top Venues

Human gene therapy

Experimental lung research

Expert opinion on biological therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandra McCarron, Kak-Ming Ling, Samuel T Montgomery, Kelly M Martinovich, Patricia Cmielewski, Nathan Rout-Pitt, Anthony Kicic, David Parsons, Martin Donnelley
Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models. Gene therapy (2024)
Martin Donnelley, Patricia Cmielewski, Emma Knight, Chantelle Carpentieri, Alexandra McCarron, Nathan Rout-Pitt, David Parsons, Nigel Farrow
Repeat or single-dose lentiviral vector administration to mouse lungs? It's all about the timing. Gene therapy (2023)
Martin Donnelley, David Parsons, Ivanka Prichard
Perceptions of airway gene therapy for cystic fibrosis. Expert opinion on biological therapy (2022)
Alexandra McCarron, Patricia Cmielewski, Victoria Drysdale, David Parsons, Martin Donnelley
Effective viral-mediated lung gene therapy: is airway surface preparation necessary? Gene therapy (2022)
Victoria Drysdale, Patricia Cmielewski, Martin Donnelley, Nicole Reyne, David Parsons, Alexandra McCarron
Comparison of Physical Perturbation Devices for Enhancing Lentiviral Vector-Mediated Gene Transfer to the Airway Epithelium. Human gene therapy 33 (19-20) (2022)
Chantelle Carpentieri, Nigel Farrow, Patricia Cmielewski, Nathan Rout-Pitt, Alexandra McCarron, Emma Knight, David Parsons, Martin Donnelley
The Effects of Conditioning and Lentiviral Vector Pseudotype on Short- and Long-Term Airway Reporter Gene Expression in Mice. Human gene therapy 32 (15-16) (2021)
Nathan Rout-Pitt, Martin Donnelley, David Parsons
In vitro optimization of miniature bronchoscope lentiviral vector delivery for the small animal lung. Experimental lung research 47 (9) (2021)